| Application number | Title of the application | Filing Date | Status |
|---|
Array
(
[id] => 18649524
[patent_doc_number] => 20230295340
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => MUC1* ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 18/062377
[patent_app_country] => US
[patent_app_date] => 2022-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18795
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18062377
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/062377 | MUC1* ANTIBODIES | Dec 5, 2022 | Abandoned |
Array
(
[id] => 18376017
[patent_doc_number] => 20230151099
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-18
[patent_title] => COMBINATION THERAPIES OF HDAC INHIBITORS AND PD-L1 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/993567
[patent_app_country] => US
[patent_app_date] => 2022-11-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30957
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17993567
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/993567 | COMBINATION THERAPIES OF HDAC INHIBITORS AND PD-L1 INHIBITORS | Nov 22, 2022 | Pending |
Array
(
[id] => 18612385
[patent_doc_number] => 20230279117
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => ANTI-PD-L1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS
[patent_app_type] => utility
[patent_app_number] => 18/050441
[patent_app_country] => US
[patent_app_date] => 2022-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15731
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18050441
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/050441 | ANTI-PD-L1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS | Oct 26, 2022 | Abandoned |
Array
(
[id] => 18626658
[patent_doc_number] => 20230285458
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-14
[patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS
[patent_app_type] => utility
[patent_app_number] => 18/048489
[patent_app_country] => US
[patent_app_date] => 2022-10-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36375
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18048489
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/048489 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | Oct 20, 2022 | Abandoned |
Array
(
[id] => 18466979
[patent_doc_number] => 20230201259
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS
[patent_app_type] => utility
[patent_app_number] => 18/048796
[patent_app_country] => US
[patent_app_date] => 2022-10-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36337
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18048796
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/048796 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | Oct 20, 2022 | Abandoned |
Array
(
[id] => 18536019
[patent_doc_number] => 20230241106
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-03
[patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS
[patent_app_type] => utility
[patent_app_number] => 18/047234
[patent_app_country] => US
[patent_app_date] => 2022-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36746
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18047234
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/047234 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | Oct 16, 2022 | Abandoned |
Array
(
[id] => 18449537
[patent_doc_number] => 20230190813
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS
[patent_app_type] => utility
[patent_app_number] => 18/047195
[patent_app_country] => US
[patent_app_date] => 2022-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36435
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18047195
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/047195 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | Oct 16, 2022 | Abandoned |
Array
(
[id] => 18536020
[patent_doc_number] => 20230241107
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-03
[patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS
[patent_app_type] => utility
[patent_app_number] => 18/047236
[patent_app_country] => US
[patent_app_date] => 2022-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36382
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18047236
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/047236 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS | Oct 16, 2022 | Abandoned |
Array
(
[id] => 18308802
[patent_doc_number] => 20230112702
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => NUCLEASE-MEDIATED MODULATION OF GENE EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 17/961763
[patent_app_country] => US
[patent_app_date] => 2022-10-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27091
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 121
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17961763
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/961763 | NUCLEASE-MEDIATED MODULATION OF GENE EXPRESSION | Oct 6, 2022 | Abandoned |
Array
(
[id] => 18451513
[patent_doc_number] => 20230192791
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS
[patent_app_type] => utility
[patent_app_number] => 17/934663
[patent_app_country] => US
[patent_app_date] => 2022-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39834
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17934663
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/934663 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | Sep 22, 2022 | Abandoned |
Array
(
[id] => 18193024
[patent_doc_number] => 20230046543
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-16
[patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS
[patent_app_type] => utility
[patent_app_number] => 17/934673
[patent_app_country] => US
[patent_app_date] => 2022-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39885
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17934673
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/934673 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | Sep 22, 2022 | Abandoned |
Array
(
[id] => 18389952
[patent_doc_number] => 20230158170
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => IL-1Ra GENE THERAPY FOR INTERVERTEBRAL DISC DEGENERATION
[patent_app_type] => utility
[patent_app_number] => 17/821761
[patent_app_country] => US
[patent_app_date] => 2022-08-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25097
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -39
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17821761
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/821761 | IL-1Ra GENE THERAPY FOR INTERVERTEBRAL DISC DEGENERATION | Aug 22, 2022 | Pending |
Array
(
[id] => 18449367
[patent_doc_number] => 20230190643
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => IMPLANT FOR TREATMENT OF AN OCULAR CONDITION
[patent_app_type] => utility
[patent_app_number] => 17/868021
[patent_app_country] => US
[patent_app_date] => 2022-07-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37877
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17868021
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/868021 | IMPLANT FOR TREATMENT OF AN OCULAR CONDITION | Jul 18, 2022 | Abandoned |
Array
(
[id] => 18242827
[patent_doc_number] => 20230075138
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-09
[patent_title] => METHODS FOR TREATING AND EVALUATING COVID-19 PATIENTS
[patent_app_type] => utility
[patent_app_number] => 17/863877
[patent_app_country] => US
[patent_app_date] => 2022-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7924
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17863877
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/863877 | METHODS FOR TREATING AND EVALUATING COVID-19 PATIENTS | Jul 12, 2022 | Pending |
Array
(
[id] => 18420480
[patent_doc_number] => 20230174942
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => NOVEL FABRICATION OF CORONARY BASED DECELLULARIZED HEART FLAPS TO TREAT ANEURYSM FOLLOWING MYOCARDIAL INFARCTION
[patent_app_type] => utility
[patent_app_number] => 17/862803
[patent_app_country] => US
[patent_app_date] => 2022-07-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12812
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17862803
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/862803 | NOVEL FABRICATION OF CORONARY BASED DECELLULARIZED HEART FLAPS TO TREAT ANEURYSM FOLLOWING MYOCARDIAL INFARCTION | Jul 11, 2022 | Abandoned |
Array
(
[id] => 18077424
[patent_doc_number] => 20220403036
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-22
[patent_title] => P-SELECTIN INHIBITOR, COMPOSITIONS THEREOF AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/842580
[patent_app_country] => US
[patent_app_date] => 2022-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8450
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17842580
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/842580 | P-SELECTIN INHIBITOR, COMPOSITIONS THEREOF AND METHODS OF USE THEREOF | Jun 15, 2022 | Abandoned |
Array
(
[id] => 18036080
[patent_doc_number] => 20220380295
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-01
[patent_title] => METHOD FOR SEPARATING AND PREPARING MULTIPLE ISOMER COMPOUNDS FROM SEABUCKTHORN POMACE
[patent_app_type] => utility
[patent_app_number] => 17/743281
[patent_app_country] => US
[patent_app_date] => 2022-05-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2815
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 178
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17743281
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/743281 | METHOD FOR SEPARATING AND PREPARING MULTIPLE ISOMER COMPOUNDS FROM SEABUCKTHORN POMACE | May 11, 2022 | Abandoned |
Array
(
[id] => 19002042
[patent_doc_number] => 20240066113
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-29
[patent_title] => MESSENGER RNA VACCINES AGAINST WIDE SPECTRUM OF CORONAVIRUS VARIANTS
[patent_app_type] => utility
[patent_app_number] => 18/029758
[patent_app_country] => US
[patent_app_date] => 2022-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16205
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18029758
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/029758 | MESSENGER RNA VACCINES AGAINST WIDE SPECTRUM OF CORONAVIRUS VARIANTS | Apr 11, 2022 | Pending |
Array
(
[id] => 17911421
[patent_doc_number] => 20220313816
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-06
[patent_title] => COMPOSITIONS AND METHODS FOR ANTIBODY-AS-ADJUVANT VACCINES AND THERAPEUTICS
[patent_app_type] => utility
[patent_app_number] => 17/657696
[patent_app_country] => US
[patent_app_date] => 2022-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6775
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17657696
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/657696 | COMPOSITIONS AND METHODS FOR ANTIBODY-AS-ADJUVANT VACCINES AND THERAPEUTICS | Mar 31, 2022 | Abandoned |
Array
(
[id] => 17850470
[patent_doc_number] => 20220280511
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-08
[patent_title] => CDK4/6 INHIBITORS FOR THE TREATMENT OF PSORIASIS
[patent_app_type] => utility
[patent_app_number] => 17/707741
[patent_app_country] => US
[patent_app_date] => 2022-03-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11738
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17707741
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/707741 | CDK4/6 INHIBITORS FOR THE TREATMENT OF PSORIASIS | Mar 28, 2022 | Pending |